PracticeUpdate: Conference Series - The Best of ICIEM 2017

THE SIGNS & SYMPTOMS OF COULD BE UNFOLDING IN FRONT OF YOU… BUT WILL YOU SEE THEM IN TIME? 1-3 MPS I OR II Left untreated, patients can face a reduced life expectancy of as little as 10 years. 2,4

Coarse facial features

*Exhibited by patients with MPS I only. 3

TREATMENTS ARE AVAILABLE, SO DON’T DELAY. SUSPECT MPS TODAY. If you suspect MPS I or II proceed to order a urinary metabolic screen (including a urinary GAG test), or refer to your local metabolic physicians for further information and advice.** **Aim to include as much clinical information as possible when requesting a metabolic screen.

MPS: mucopolysaccharidosis; GAG: glycosaminoglycans. Images reproduced with permission. References: 1. Muenzer J et al. Orphanet Journal of Rare Diseases 2017; 12: 82–91. 2. Beck M et al. Genet Med 2014; 16: 759–65. 3. Burton B & Giugliani R. Eur J Pediatr 2012; 171: 631–9. 4. Wraith J et al. Genet Med 2008; 10: 508–16. Sanoˆ-aventis Australia Pty Ltd trading as Sanoˆ Genzyme ABN 31 008 558 807. Talavera Corporate Centre, Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113. GZANZ.ELAP.16.09.0171b(1)e. August 2017. AM7073.

Made with FlippingBook flipbook maker